药捷安康-B(02617)午后涨超16%，高见34港元，再创上市新高。截至发稿，涨16.18%，报33.75港元，成交额2089.53万港元。消息面上，药捷安康宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼(TT-00420)，已获美国食品药物管理局(FDA)授予治疗转移性去势抵抗性前列腺癌的快速通道认证。公司表示，替恩戈替尼目前处于全球三期注册实验的多靶点激酶抑制剂，靶向FGFR/VEGFR、...
Source Link药捷安康-B(02617)午后涨超16%，高见34港元，再创上市新高。截至发稿，涨16.18%，报33.75港元，成交额2089.53万港元。消息面上，药捷安康宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼(TT-00420)，已获美国食品药物管理局(FDA)授予治疗转移性去势抵抗性前列腺癌的快速通道认证。公司表示，替恩戈替尼目前处于全球三期注册实验的多靶点激酶抑制剂，靶向FGFR/VEGFR、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.